Phosphodiesterase III inhibition promotes differentiation and survival of oligodendrocyte progenitors and enhances regeneration of ischemic white matter lesions in the adult mammalian brain
- PMID: 19826432
- PMCID: PMC2949130
- DOI: 10.1038/jcbfm.2009.210
Phosphodiesterase III inhibition promotes differentiation and survival of oligodendrocyte progenitors and enhances regeneration of ischemic white matter lesions in the adult mammalian brain
Abstract
Vascular dementia is caused by blockage of blood supply to the brain, which causes ischemia and subsequent lesions primarily in the white matter, a key characteristic of the disease. In this study, we used a chronic cerebral hypoperfusion rat model to show that the regeneration of white matter damaged by hypoperfusion is enhanced by inhibiting phosphodiesterase III. A rat model of chronic cerebral hypoperfusion was prepared by bilateral common carotid artery ligation. Performance at the Morris water-maze task, immunohistochemistry for bromodeoxyuridine, as well as serial neuronal and glial markers were analyzed until 28 days after hypoperfusion. There was a significant increase in the number of oligodendrocyte progenitor cells in the brains of patients with vascular dementia as well as in rats with cerebral hypoperfusion. The oligodendrocyte progenitor cells subsequently underwent cell death and the number of oligodendrocytes decreased. In the rat model, treatment with a phosphodiesterase III inhibitor prevented cell death, markedly increased the mature oligodendrocytes, and promoted restoration of white matter and recovery of cognitive decline. These effects were cancelled by using protein kinase A/C inhibitor in the phosphodiesterase III inhibitor group. The results of our study indicate that the mammalian brain white matter tissue has the capacity to regenerate after ischemic injury.
Figures







References
-
- Arvidsson A, Collin T, Kirik D, Kokaia Z, Lindvall O. Neuronal replacement from endogenous precursors in the adult brain after stroke. Nat Med. 2002;8:963–970. - PubMed
-
- Bansal R, Pfeiffer SE. FGF-2 converts mature oligodendrocytes to a novel phenotype. J Neurosci Res. 1997;50:215–228. - PubMed
-
- Barnett AH, Bradbury AW, Brittenden J, Crichton B, Donnelly R, Homer-Vanniasinkam S, Mikhailidis DP, Stansby G. The role of cilostazol in the treatment of intermittent claudication. Curr Med Res Opin. 2004;20:1661–1670. - PubMed
-
- Brown WR, Moody DM, Thore CR, Challa VR. Cerebrovascular pathology in Alzheimer's disease and leukoaraiosis. Ann N Y Acad Sci. 2000;903:39–45. - PubMed
-
- Butt AM. Structure and Function of Oligodendrocytes. New York, USA: Oxford University Press; 2004.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical